Valeant to sweeten pill for Allergan
This article was originally published in Scrip
Executive Summary
Valeant Pharmaceuticals will sweeten its unsolicited $48bn offer for Botox-maker Allergan, with activist shareholder Pershing Square - which supports the bid - saying it plans to ask for a non-binding vote to get Allergan to negotiate.